|
|
|
An Icelandic volcano didn't slow down the biggest Expo yet.
By Kevin Davies
May 18, 2010 | First Base | Two years ago, walking around the exhibit hall at Bio-IT World Expo, an occasional contributor to this publication came up to me and said, “It feels like this event is finally coming of age.” If I didn’t entirely believe him then, I do now. The palpable energy throughout the conference, from the 100+ exhibitors to the packed conference sessions and a magnificent annual awards dinner (which we’ll cover in our next issue), was ample testimony to the growing buy-in from organizations that are struggling to manage and leverage biological, chemical, clinical, and health care data.
Thanks to the remarkable efforts of producers, meeting planners, and our many colleagues at Cambridge Healthtech Institute, which produces the Expo, the Icelandic ash cloud wreaked minimal damage to this year’s conference program.
Naturally, we were disappointed not to host some two dozen European speakers, particularly Alex Bateman (Wellcome Trust Sanger Institute), who was unable to accept his 2010 Benjamin Franklin Award from Bioinformatics Organization president Jeff Bizzaro. Many speakers were still able to participate via Web conference, phone, or video. Ironically, perhaps the only European speaker who made it across the pond was deCODE Genetics founder Kari Stefansson, who reported clear skies west of Reykjavik.
Elsewhere in this issue, we present coverage of the keynotes and other noted speakers at this year’s conference (see, "Four Secrets to Success", "Harnessing (and Securing) Meaningful Data", and "Clouds and More Clouds in Seattle"). The only problem with a conference growing as fast as this is it makes it impossible to hear half the speakers one would like. But a few select highlights were as follows:
- Speaking of clouds, opening day saw the official launch of DNAnexus, a Stanford spin-off led by Andreas Sundquist, which supplies cost-effective next-generation sequence data management capabilities in the Cloud (see, "Cloud Convergence"). It will be interesting to monitor how this offering appeals to the next-gen user community.
- Alex Bateman received the 2010 Benjamin Franklin Award via a pre-recorded video. Bateman discussed his goal of creating “a periodic table for biology,” focusing on the accurate classification of all proteins (some 15 million) and RNA. Bateman said he was still looking for another 20-30,000 protein domain families, which should just about take him up to retirement age.
- Les Jordan (Microsoft) laid out the future of the BioIT Alliance, the community that Microsoft launched at Bio-IT World Expo in 2006. Microsoft is spinning off the Alliance as an independent standards organization, incorporated in the state of Oregon, focusing on translational medicine. Microsoft will remain involved as a sponsor but Jordan declared, “We’re trying to make it more open, include other voices, so this does not have the appearance of being a Microsoft-centric group. We want to play nice in the sandbox!” A recruitment drive for sponsors (up to 11) and members is ongoing.
- Taking a leaf out of Stephen Friend’s (Sage Bionetworks) playbook, Pfizer’s Matteo Tomasso and Merck’s Martin Leach delivered an excellent joint presentation on how big pharma can take a more altruistic point-of-view with regard to deploying open-source tools, even divesting some of the legacy software tools and custom code the companies have amassed and written over the years. Alternatively, there is value to selling off assets (such as Rosetta) and licensing back with additional capabilities.
- The BioTeam’s Chris Dagdigian delivered his annual “trends in the trenches” review of hardware and software do’s and don’ts. On the hardware side, he was seeing a slower adoption of 10-GB ethernet than expected, but a spike in Sun (now Oracle) Grid Engine. “Private Clouds are crap,” he said, calling the area overhyped and making him very cynical of marketing people slapping “the ‘C’ word” on old products.
As for the public Cloud, he said, “We’ve gone from cutting-edge cool to mainstream/boring really quickly!” However, “You won’t be throwing away data centers in next two years.” Dagdigian also praised Amylin for performing a meticulous appraisal of IT costs across the organization, which led them to pursue on-demand solutions (see, “Amazon, Amylin, and the Cloud,” Bio•IT World, Nov 2009).
We are very excited to be taking the show on the road again this October for the second annual Bio-IT World Europe conference, which will be held from October 5-7, 2010, in conjunction with BioTechnica in Hannover, Germany. See the full program at: http://www.bio-itworldexpo.com/europe
This article also appeared in the May-June 2010 issue of Bio-IT World Magazine. Subscriptions are free for qualifying individuals. Apply today.
Turning Genomics Data into Practical Insight With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can: - Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines.
- Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image).
Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands.
New Complimentary Market Survey… Collaborations and Communications Within Drug Discovery Research This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns. An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
Scientific Software Engineer Boston MA $70,000 to $95,000
Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET.
Apply at http://jobs.tessella.com
Early Access Collaborations Managers Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes. As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers. This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions. It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply
Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules. It is therefore suitable for use in a variety of markets including scientific research and clinical applications. As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team. The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market. This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company. Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial leadership, who wish to apply a fresh approach to existing markets. Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries. We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products. Click to Apply
|
|
|